Unicycive Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Unicycive Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • Unicycive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$4.1M, a 5.47% increase year-over-year.
  • Unicycive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$23M, a 18.1% increase year-over-year.
  • Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$30.5M, a 69.1% decline from 2022.
  • Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.1M, a 80.3% decline from 2021.
  • Unicycive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$10M, a 342% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$30.5M -$12.5M -69.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$18.1M -$8.04M -80.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$10M -$7.75M -342% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$2.26M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.